Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results Meeting Abstract
| Authors: | Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Borrego, M. R.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; Turner, N. C.; Sophos, N.; Zarate, J. P.; Arce, C.; Shen, Y. M.; Chia, S. K. L. |
| Abstract Title: | Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368300162 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.1006 |
| Notes: | Meeting Abstract: 1006 -- Source: Wos |
